NSCLC Coverage From Every Angle
Advertisement
Advertisement

Martin Reck, MD, PhD, on Selecting Immunotherapy

Posted: Tuesday, November 14, 2017

Although nivolumab, for instance, may be prescribed for patients with low or no PD-L1 expression, how likely are you to select immunotherapy for such patients?